Illumina (NASDAQ: ILMN)
Key Data Points
Illumina Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Illumina Company Info
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
News & Analysis
Why Illumina Stock Got Mashed on Monday
Why Illumina Stock Is Sinking Today
Illumina Surpasses EPS Estimates
Illumina reported better-than-expected earnings, supported by operational efficiencies, despite facing market challenges.
Why Illumina Stock Plummeted Today
Illumina Surpasses EPS Expectations
Illumina exhibited stable performance in its latest earnings, meeting revenue estimates while navigating rising expenses and legal costs.
Illumina's Q1 Earnings Beat Estimates
Illumina's Q1 2024 earnings outpaced market expectations.
Why Illumina Stock Zoomed Higher on Thursday
The company's chances for winning an important legal battle have improved dramatically.
Why Illumina Stock Mashed the Market on Monday
Investors usually get more bullish when a top manager buys more heavily into their company.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

Illumina CEO Steps Down; Grail Soap Opera Continues
And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles."

Why Illumina Could Be a Health Tech Powerhouse for Your Portfolio
The sky is the limit for the leader in DNA sequencing.

Our Top Stock Ideas in Silicon Valley’s Biggest Bet in Healthcare
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
INDUSTRY FOCUS // Healthcare // 02-08-2017
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.